Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
First Claim
Patent Images
1. A method for the treatment of a patient having International Small Animal Cardiac Health Council (ISACHC) Class I asymptomatic heart failure comprising:
- administering to a non-human patient having ISACHC Class I asymptomatic heart failure a therapeutically effective amount of a phosphodiesterase type III (PDE III) inhibitor or a Ca2+-sensitizing agent selected from the group consisting of pimobendan, milrinone, levosimendan, amrinone, enoximone, and piroximone,wherein said therapeutically effective amount is effective to prolong the time until onset of symptoms of ISACHC Class II or Class III heart failure in the patient.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the prolongation of time until onset of clinical symptoms in patients having an asymptomatic (occult) heart failure or for the reduction of heart size in patients having symptomatic or asymptomatic (occult) heart failure.
-
Citations
14 Claims
-
1. A method for the treatment of a patient having International Small Animal Cardiac Health Council (ISACHC) Class I asymptomatic heart failure comprising:
-
administering to a non-human patient having ISACHC Class I asymptomatic heart failure a therapeutically effective amount of a phosphodiesterase type III (PDE III) inhibitor or a Ca2+-sensitizing agent selected from the group consisting of pimobendan, milrinone, levosimendan, amrinone, enoximone, and piroximone, wherein said therapeutically effective amount is effective to prolong the time until onset of symptoms of ISACHC Class II or Class III heart failure in the patient. - View Dependent Claims (2, 3, 4, 5, 6, 7)
-
-
8. A method for prolongation of the time until onset of clinical symptoms in a patient having International Small Animal Cardiac Health Council (ISACHC) Class I asymptomatic heart failure comprising:
administering to a non-human patient having ISACHC Class I asymptomatic heart failure a therapeutically effective amount of pimobendan. - View Dependent Claims (9, 10, 11, 12, 13, 14)
Specification